The DOI matches its Crossref record; 241 of the 244 references it cites were found in a registry or an index.
Neuroinflammation in Alzheimer's disease
Open accessAbstract
Increasing evidence suggests that Alzheimer's disease pathogenesis is not restricted to the neuronal compartment, but includes strong interactions with immunological mechanisms in the brain. Misfolded and aggregated proteins bind to pattern recognition receptors on microglia and astroglia, and trigger an innate immune response characterised by release of inflammatory mediators, which contribute to disease progression and severity. Genome-wide analysis suggests that several genes that increase the risk for sporadic Alzheimer's disease encode factors that regulate glial clearance of misfolded proteins and the inflammatory reaction. External factors, including systemic inflammation and obesity, are likely to interfere with immunological processes of the brain and further promote disease progression. Modulation of risk factors and targeting of these immune mechanisms could lead to future therapeutic or preventive strategies for Alzheimer's disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“since there is a strong correlation between immune activation and oxidative damage in neurodegenerative disease [42,43,44]”
From ROS Generation in Microglia: Understanding Oxidative Stress and Inflammation in Neurodegenerative Disease (2020) · cites this paper as [42]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Chronic low-grade inflammation contributes to both the onset and progression of AD and PD through microglial activation and pro-inflammatory cytokine release, accelerating neuronal injury [4].”
From What Are the Key Biological Pathways Through Which Lifestyle Factors Influence Neurodegeneration? (2025) · cites this paper as [4]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“This aligns with biological evidence highlighting the roles of diet and circadian regulation in modulating neuroinflammation and glymphatic clearance [4,5].”
From What Are the Key Biological Pathways Through Which Lifestyle Factors Influence Neurodegeneration? (2025) · cites this paper as [4]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“During early stages of AD, microglia contribute to Αβ clearance15”
From Amyloid-β induces lipid droplet-mediated microglial dysfunction via the enzyme DGAT2 in Alzheimer’s disease (2025) · cites this paper as [15]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Converging lines of evidence from human genetics, neuroimaging and post-mortem brain tissue studies suggest that microglia are major contributors to molecular and phenotypic changes, including synaptic loss and Aβ clearance, in the AD brain [4].”
From Heterozygous expression of the Alzheimer’s disease-protective PLCγ2 P522R variant enhances Aβ clearance while preserving synapses (2022) · cites this paper as [4]
Experimental — accuracy not yet measured
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Likewise, microglia, the brain-resident immunocompetent macrophages, also recognize Aβ oligomers via receptors such as CD36, toll-like receptor 4 (TLR4) and TLR6 and triggering receptor expressed on myeloid cells 2 (TREM2), acquiring specific AD-associated phenotypes [14,15,16].”
From Emerging Role of miR-21-5p in Neuron–Glia Dysregulation and Exosome Transfer Using Multiple Models of Alzheimer’s Disease (2022) · cites this paper as [14]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In AD, however, a subset of astrocytes undergoes reactive transformation, adopting inflammatory and metabolically altered states that compromise synaptic support and promote neurotoxicity (Heneka et al., 2015; Nassar et al., 2022).”
From Cell-specific MicroRNA networks orchestrate the pathogenesis of Alzheimer’s disease (2026) · cites this paper as Heneka et al., 2015
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In AD, these networks become maladaptive, leading to sustained inflammation, impaired synaptic support, defective myelination (Nasrabady et al.; 2018, Zhou et al., 2022), and breakdown of the blood-brain barrier (BBB), ultimately amplifying neurodegeneration (Heneka et al., 2015; Sweeney et al., 2018).”
From Cell-specific MicroRNA networks orchestrate the pathogenesis of Alzheimer’s disease (2026) · cites this paper as Heneka et al., 2015
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Receptors on microglia can bind Aβ fibrils, driving an inflammatory response similar to the M1 (proinflammatory) phenotype observed outside the central nervous system [84].”
From The neuropathological diagnosis of Alzheimer's disease (2019) · cites this paper as [84]
The cited source says what the claim attributes to it.
In the citing paper
“The reactive gliosis, encompassing microgliosis and astrogliosis, are prevalent neuropathological hallmarks observed in the brains of both human AD and mouse models of Aβ amyloidosis8,15,16.”
From Effects of SPI1-mediated transcriptome remodeling on Alzheimer's disease-related phenotypes in mouse models of Aβ amyloidosis (2024) · cites this paper as [15]
The cited source says what the claim attributes to it.
In the citing paper
“Amyloid-associated gliosis is consistently observed in the brains of AD patients15 and amyloidosis mouse models8,16.”
From Effects of SPI1-mediated transcriptome remodeling on Alzheimer's disease-related phenotypes in mouse models of Aβ amyloidosis (2024) · cites this paper as [15]
The cited source says what the claim attributes to it.
In the citing paper
“Increasing clinical evidence suggests that neuroinflammation functions as a vital factor in AD pathogenesis (2)”
From Understanding monocyte-driven neuroinflammation in Alzheimer’s disease using human cortical organoid microphysiological systems (2025) · cites this paper as [2]
The cited source says what the claim attributes to it.
In the citing paper
“altered microglial function has been implicated in the progression of AD”
From Heterozygous expression of the Alzheimer’s disease-protective PLCγ2 P522R variant enhances Aβ clearance while preserving synapses (2022) · cites this paper as [4]
The cited source says what the claim attributes to it.
In the citing paper
“Furthermore, Aβ may initiate microglial activation, resulting in microglial migration to plaques, phagocytosis, and enzymatic degradation of Aβ [37].”
From Cerebrospinal fluid levels of the neurotrophic factor neuroleukin are increased in early Alzheimer’s disease, but not in cerebral amyloid angiopathy (2021) · cites this paper as [37]
The cited source says what the claim attributes to it.
In the citing paper
“Astrocytes become reactive and inflammatory, while microglia transition into chronically activated states that can amplify neuroinflammation (Heneka et al., 2015; Sofroniew and Vinters, 2010).”
From Cell-specific MicroRNA networks orchestrate the pathogenesis of Alzheimer’s disease (2026) · cites this paper as Heneka et al., 2015
The cited source says what the claim attributes to it.
In the citing paper
“Microglia, the brain's primary immune cells, play a dual and stage-dependent role in AD, initially contributing to Aβ clearance but transitioning into a chronically reactive, pro-inflammatory state under persistent pathological stress (Hansen et al., 2017; Heneka et al., 2015).”
From Cell-specific MicroRNA networks orchestrate the pathogenesis of Alzheimer’s disease (2026) · cites this paper as Heneka et al., 2015
The cited source says what the claim attributes to it.
In the citing paper
“Neuroinflammation is a prominent feature of the neuropathology of Alzheimer’s disease (AD), in addition to β-amyloid (Aβ) plaques, tau-containing neurofibrillary tangles (NFT), and synaptic dysfunction followed by neurodegeneration [1].”
From 25-Hydroxycholesterol amplifies microglial IL-1β production in an apoE isoform-dependent manner (2020) · cites this paper as [1]
The cited source says what the claim attributes to it.
In the citing paper
“Emerging evidence indicates that neuroinflammation, mediated by activated glial cells, plays a fundamental role in the pathogenesis and neurodegeneration of AD [1].”
From 25-Hydroxycholesterol amplifies microglial IL-1β production in an apoE isoform-dependent manner (2020) · cites this paper as [1]
The cited source says what the claim attributes to it.
In the citing paper
“While amyloid-β plaques and TAU tangles have long been recognized as pathological hallmarks of AD, emerging research highlights the critical role of neuroinflammation in disease progression [1, 35–37].”
From microRNA-132 attenuates inflammation in induced pluripotent stem cell-derived microglia from Alzheimer’s disease patients (2026) · cites this paper as [35]
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Galectin-3 (Gal-3) is a key protein involved in neuroinflammation and is strongly upregulated in neurodegenerative conditions16.”
From Deletion of SPI1 in microglia exacerbates amyloid pathology by impairing microglial response in Alzheimer’s disease models (2026) · cites this paper as [16]
Experimental — accuracy not yet measuredIn the citing paper
“Neuroinflammation is a common feature of AD9 and GWAS have associated several immune-related genes with AD including ABCA7, CD33, CLU, CR1, MS4A10, 11 and recently TREM2.12, 13”
From Whole-genome sequencing suggests a chemokine gene cluster that modifies age at onset in familial Alzheimer's disease (2015) · cites this paper as [9]
In the citing paper
“Clinical evidence shows that TauO and brain inflammation also appear in the preclinical or prodromal AD stage, many decades prior to the onset of dementia. 100”
From Senescence, brain inflammation, and oligomeric tau drive cognitive decline in Alzheimer's disease: Evidence from clinical and preclinical studies (2024) · cites this paper as [100]
In the citing paper
“Furthermore, since the immune response exists throughout the pathological progress of AD [104, 105], suggesting that it may also participate in and aggravate the disease development.”
From Tau and neuroinflammation in Alzheimer’s disease: interplay mechanisms and clinical translation (2023) · cites this paper as [104]
In the citing paper
“Plaques were evident in multiple brain regions by 4mo in male and female 5xFAD mice, concomitant with the stereotypical activation and gliosis of plaque- and non-plaque-associated microglia (PAM and NPAM, respectively; Fig. 1A-C) [52, 53].”
From Microglia facilitate loss of perineuronal nets in the Alzheimer's disease brain (2020) · cites this paper as [52]
In the citing paper
“The neurotoxicity of microglial cells may also be related to their expression of tau, which is triggered by the deposition of Aβ in the brain and is known to be neurotoxic149.”
From Microglial signatures and their role in health and disease (2018) · cites this paper as [149]
In the citing paper
“In AD brains reactive microglia has been found colocalized with amyloid plaques. In addition, the reactive astrocytes accumulate around senile plaques next to the activated microglia (Heneka et al., 2015).”
From The role of microglia in retinal neurodegeneration: Alzheimer’s disease, parkinson, and glaucoma. (2017) · cites this paper as Heneka et al., 2015
In the citing paper
“The sustained exposure to cytokines, chemokines and Aβ, could be responsible for the functional impairment of microglial cells located around Aβ− deposits (Heneka et al., 2015).”
From The role of microglia in retinal neurodegeneration: Alzheimer’s disease, parkinson, and glaucoma. (2017) · cites this paper as Heneka et al., 2015
In the citing paper
“Microglial senescence can enhance the sensitivity of microglia to inflammatory stimuli; this phenomenon is called “priming” (Heneka et al., 2015).”
From The role of microglia in retinal neurodegeneration: Alzheimer’s disease, parkinson, and glaucoma. (2017) · cites this paper as Heneka et al., 2015
In the citing paper
“Popular neuroprotective strategies for AD management consist of discovering small molecules with the ability to block these Aβ interactions with intracellular and extracellular targets to avoid caspase activation and the expression of proapoptotic proteins, to reduce the stress kinase signaling cascades, to inhibit tau protein phosphorylation, to counterpoise cholinergic functional loss, and to bo”
From The Multifaceted Role of Neuroprotective Plants in Alzheimer’s Disease Treatment (2022) · cites this paper as [37]
In the citing paper
“The FDA has approved two drugs for mild cognitive impairment (MCI) to early, mild stages of AD after years of failed clinical trials. They are aducanemab, and lecanemab, among which aducanemab received accelerated approval [14, 15].”
From Current therapeutics for Alzheimer’s disease and clinical trials (2024) · cites this paper as [15]
In the citing paper
“Neuroinflammation and oxidative stress (OS) are undoubtedly hallmarks of neurodegeneration, contributing to disease progression.”
From ROS Generation in Microglia: Understanding Oxidative Stress and Inflammation in Neurodegenerative Disease (2020) · cites this paper as [42]
In the citing paper
“These genetic findings are further supported by the common observation of aberrantly activated microglia in pathologically relevant AD brain regions, including within and surrounding Aβ plaques [59, 60].”
From Systems-based proteomics to resolve the biology of Alzheimer’s disease beyond amyloid and tau (2021) · cites this paper as [60]
In the citing paper
“Indeed, many of the risk genes associated with AD mediate their effects through microglia, the brain‐resident macrophages (Glass et al, 2010; Heneka et al, 2015; Nott et al, 2019).”
From Mechanisms of DNA damage-mediated neurotoxicity in neurodegenerative disease (2022) · cites this paper as Heneka et al, 2015
In the citing paper
“Neuroinflammation has been identified as a key contributor to the pathobiology of AD [2–4]”
In the citing paper
“and occurs at early disease stages [2, 5–7]”
In the citing paper
“Peripheral inflammation may exacerbate neuroinflammation [2].”
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Molecular Mechanisms of Depression: Perspectives on New Treatment Strategies
Lang, U. E., & Borgwardt, S. (2013) · Cellular Physiology and Biochemistry · doi:10.1159/000350094 · Cited by 8,526
Glutamate neurotoxicity and diseases of the nervous system
Choi, D. W. (1988) · Neuron · doi:10.1016/0896-6273(88)90162-6 · Cited by 8,188
The chemokine system in diverse forms of macrophage activation and polarization
MANTOVANI, A., SICA, A., SOZZANI, S., ALLAVENA, P., VECCHI, A., & LOCATI, M. (2004) · Trends in Immunology · doi:10.1016/j.it.2004.09.015 · Cited by 6,534
Iliff, J. J., Wang, M., Liao, Y., Plogg, B. A., Peng, W., Gundersen, G. A., Benveniste, H., Vates, G. E., Deane, R., Goldman, S. A., et al. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3003748 · Cited by 5,824
MANTOVANI, A., SOZZANI, S., LOCATI, M., ALLAVENA, P., & SICA, A. (2002) · Trends in Immunology · doi:10.1016/s1471-4906(02)02302-5 · Cited by 5,528
Schroder, K., & Tschopp, J. (2010) · Cell · doi:10.1016/j.cell.2010.01.040 · Cited by 5,475
Astrocytes: Biology and pathology
Sofroniew, M. V., & Vinters, H. V. (2010) · Acta Neuropathologica · doi:10.1007/s00401-009-0619-8 · Cited by 5,196
Fate Mapping Analysis Reveals That Adult Microglia Derive from Primitive Macrophages
Ginhoux, F., Greter, M., Leboeuf, M., Nandi, S., See, P., Gokhan, S., Mehler, M. F., Conway, S. J., Ng, L. G., Stanley, E. R., et al. (2010) · Science · doi:10.1126/science.1194637 · Cited by 5,175
Richness of human gut microbiome correlates with metabolic markers
Le Chatelier, E., Nielsen, T., Qin, J., Prifti, E., Hildebrand, F., Falony, G., Almeida, M., Arumugam, M., Batto, J.-M., Kennedy, S., et al. (2013) · Nature · doi:10.1038/nature12506 · Cited by 4,662
Querfurth, H. W., & LaFerla, F. M. (2010) · New England Journal of Medicine · doi:10.1056/nejmra0909142 · Cited by 4,569
Cited by
Sorted by citations
Items 801–900 of 1,118
Friend, Foe or Both? Immune Activity in Alzheimer’s Disease
Frost, G. R., Jonas, L. A., & Li, Y. (2019) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2019.00337 · Cited by 88
Díaz‐Zúñiga, J., More, J., Melgar‐Rodríguez, S., Jiménez-Unión, M., Villalobos-Orchard, F., Muñoz‐Manríquez, C., Monasterio, G., Valdés, J. L., Vernal, R., & Paula-Lima, A. C. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.588036 · Cited by 93
Vagus Nerve Stimulation as a Potential Therapy in Early Alzheimer’s Disease: A Review
Vargas‐Caballero, M., Warming, H., Walker, R., Holmes, C., Cruickshank, G. S., & Patel, B. (2022) · Frontiers in Human Neuroscience · doi:10.3389/fnhum.2022.866434 · Cited by 94
Self-citationCell models for Alzheimer’s and Parkinson’s disease: At the interface of biology and drug discovery
Cetin, S., Knez, D., Gobec, S., Kos, J., & Pišlar, A. H. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.112924 · Cited by 92
The AAA+ chaperone VCP disaggregates Tau fibrils and generates aggregate seeds in a cellular system
Saha, I., Yuste‐Checa, P., Padilha, M. D. S., Guo, Q., Körner, R., Holthusen, H., Trinkaus, V. A., Dudanova, I., Fernández‐Busnadiego, R., Baumeister, W. P., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-36058-2 · Cited by 93
Sex and Gender Differences in Neurodegenerative Diseases: Challenges for Therapeutic Opportunities
Bianco, A., Antonacci, Y., & Liguori, M. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24076354 · Cited by 90
Neuroinflammation in motor neuron disease.
Komine, O., & Yamanaka, K. (2015) · Europe PMC (PubMed Central) · doi:10.18999/nagjms.77.4.537 · Cited by 87
Self-citationMetabolic Dysfunction in Alzheimer’s Disease: From Basic Neurobiology to Clinical Approaches
Clarke, J. R., Ribeiro, F. C., Frozza, R. L., Felice, F. G. D., & Lourenco, M. V. (2018) · Journal of Alzheimer s Disease · doi:10.3233/jad-179911 · Cited by 93
Batista, A. F., Rody, T., Forny-Germano, L., Cerdeiro, S., Bellio, M., Ferreira, S. T., Munoz, D. P., & De Felice, F. G. (2021) · Journal of Neuroinflammation · doi:10.1186/s12974-021-02099-x · Cited by 91
Icariin and Its Metabolites as Potential Protective Phytochemicals Against Alzheimer’s Disease
Angeloni, C., Barbalace, M. C., & Hrelia, S. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.00271 · Cited by 86
Dementia and COVID-19, a Bidirectional Liaison: Risk Factors, Biomarkers, and Optimal Health Care
Toniolo, S., the Management Group of the EAN Dementia and Cognitive Disorders Scientific Panel, Scarioni, M., Lorenzo, F. D., Hort, J., Georges, J., Tomić, S., Nobili, F. M., & Frederiksen, K. S. (2021) · Journal of Alzheimer s Disease · doi:10.3233/jad-210335 · Cited by 86
Chu, C., Yu, L., Qi, G., Mi, Y., Wu, W., Lee, Y. K., Zhai, Q., Tian, F., & Chen, W. (2022) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2022.104556 · Cited by 87
Walker, L. C. (2020) · Free Neuropathology · doi:10.17879/freeneuropathology-2020-3025 · Cited by 113
Suresh, S., Ankul Singh, S., Rushendran, R., Vellapandian, C., & Prajapati, B. G. (2023) · Frontiers in Neurology · doi:10.3389/fneur.2023.1303111 · Cited by 93
Magistri, M., Velmeshev, D., Makhmutova, M., Patel, P., Sartor, G. C., Volmar, C., Wahlestedt, C., & Faghihi, M. A. (2016) · Current Alzheimer Research · doi:10.2174/1567205013666160427101832 · Cited by 88
Xu, J., Begley, P., Church, S. J., Patassini, S., McHarg, S., Kureishy, N., Hollywood, K. A., Waldvogel, H. J., Liu, H., Zhang, S., et al. (2016) · Scientific Reports · doi:10.1038/srep27524 · Cited by 85
Hoeijmakers, L., Heinen, Y., van Dam, A.-M., Lucassen, P. J., & Korosi, A. (2016) · Frontiers in Human Neuroscience · doi:10.3389/fnhum.2016.00398 · Cited by 85
Zheng, Q., Li, G., Wang, S., Zhou, Y., Liu, K., Gao, Y., Zhou, Y., Zheng, L., Zhu, L., Deng, Q., et al. (2021) · Science Advances · doi:10.1126/sciadv.abe1340 · Cited by 85
The Role of TDP-43 in Alzheimer’s Disease
Chang, X., Tan, M., Tan, L., & Yu, J. (2015) · Molecular Neurobiology · doi:10.1007/s12035-015-9264-5 · Cited by 85
Decreased in vivo availability of the cannabinoid type 2 receptor in Alzheimer’s disease
Ahmad, R. U., Postnov, A. A., Bormans, G. M., Versijpt, J. J., Vandenbulcke, M., & Laere, K. V. (2016) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-016-3457-7 · Cited by 88
Decreased IL-8 levels in CSF and serum of AD patients and negative correlation of MMSE and IL-1β
Hesse, R., Wahler, A., Gummert, P., Kirschmer, S., Otto, M., Tumani, H., Lewerenz, J., Schnack, C., & von Arnim, C. A. F. (2016) · BMC Neurology · doi:10.1186/s12883-016-0707-z · Cited by 81
Chen, Z., Revenko, A. S., Singh, P. K., MacLeod, A. R., Norris, E. H., & Strickland, S. (2017) · Blood · doi:10.1182/blood-2016-11-753202 · Cited by 87
Kerdiles, O., Layé, S., & Calon, F. (2017) · Trends in Food Science & Technology · doi:10.1016/j.tifs.2017.09.003 · Cited by 87
Immunomodulatory capacity of the serotonin receptor 5-HT2B in a subset of human dendritic cells
Szabó, A., Gogolák, P., Koncz, G., Földvári, Z., Pázmándi, K., Miltner, N., Póliska, S., Bácsi, A., Djurovic, S., & Rajnavölgyi, É. (2018) · Scientific Reports · doi:10.1038/s41598-018-20173-y · Cited by 85
CSF sAPPβ, YKL-40, and NfL along the ALS-FTD spectrum
Illán‐Gala, I., Alcolea, D. A., Montal, V., Dols‐Icardo, O., Muñoz, L., de Luna, N., Turón‐Sans, J., Cortés‐Vicente, E., Sánchez‐Saudinós, M. B., Subirana, A., et al. (2018) · Neurology · doi:10.1212/wnl.0000000000006383 · Cited by 86
Alpha-2-Macroglobulin, a Hypochlorite-Regulated Chaperone and Immune System Modulator
Cater, J. H., Wilson, M. R., & Wyatt, A. R. (2019) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2019/5410657 · Cited by 88
Pereira, J. B., Janelidze, S., Strandberg, O. T., Whelan, C. D., Zetterberg, H., Blennow, K., Palmqvist, S., Stomrud, E., Mattsson, N., & Hansson, O. (2022) · Nature Aging · doi:10.1038/s43587-022-00310-z · Cited by 85
Yokokura, M., Terada, T., Bunai, T., Nakaizumi, K., Takebayashi, K., Iwata, Y., Yoshikawa, E., Futatsubashi, M., Suzuki, K., Mori, N., et al. (2016) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1177/0271678x16646788 · Cited by 86
Early secure attachment as a protective factor against later cognitive decline and dementia
Walsh, E., Blake, Y., Donati, A., Stoop, R., & von Gunten, A. (2019) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2019.00161 · Cited by 84
Role of glutamate receptors and glial cells in the pathophysiology of treatment-resistant depression
Kim, Y.-K., & Na, K.-S. (2016) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2016.03.009 · Cited by 84
Kynurenic Acid Levels are Increased in the CSF of Alzheimer’s Disease Patients
González-Sánchez, M., Jiménez, J., Narváez, A., Antequera, D., Llamas-Velasco, S., Martín, A. H.-S., Molina Arjona, J. A., López de Munain, A., Lleó Bisa, A., Marco, M.-P., et al. (2020) · Biomolecules · doi:10.3390/biom10040571 · Cited by 84
Distinct Hippocampal Expression Profiles of Long Non-coding RNAs in an Alzheimer’s Disease Model
Yang, B., Xia, Z.-A., Zhong, B., Xiong, X., Sheng, C., Wang, Y., Gong, W., Cao, Y., Wang, Z., & Peng, W. (2016) · Molecular Neurobiology · doi:10.1007/s12035-016-0038-5 · Cited by 84
Recent Progress in Alzheimer’s Disease Research, Part 1: Pathology
Hane, F. T., Lee, B. Y., & Leonenko, Z. (2017) · Journal of Alzheimer s Disease · doi:10.3233/jad-160882 · Cited by 92
Understanding Epigenetics in the Neurodegeneration of Alzheimer’s Disease: SAMP8 Mouse Model
Griñán‐Ferré, C., Corpas, R., Puigoriol‐Illamola, D., Palomera‐Ávalos, V., Sanfeliu, C., & Pallàs, M. (2018) · Journal of Alzheimer s Disease · doi:10.3233/jad-170664 · Cited by 86
Zhao, B., Liu, H., Wang, J., Liu, P., Tan, X., Ren, B., Liu, Z., & Liu, X. (2018) · Journal of Agricultural and Food Chemistry · doi:10.1021/acs.jafc.7b05770 · Cited by 84
Colligris, P., de Lara, M. J. P., Colligris, B., & Pintor, J. J. (2018) · Journal of Ophthalmology · doi:10.1155/2018/8538573 · Cited by 84
Agwa, M. M., Abdelmonsif, D. A., Khattab, S. N., & Sabra, S. A. (2020) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2020.06.058 · Cited by 84
Plasma Inflammatory Cytokines Are Elevated in ALS
Tortelli, R., Zecca, C., Piccininni, M., Benmahamed, S., Dell’Abate, M. T., Barulli, M. R., Capozzo, R., Battista, P., & Logroscino, G. (2020) · Frontiers in Neurology · doi:10.3389/fneur.2020.552295 · Cited by 90
Decoding Mast Cell-Microglia Communication in Neurodegenerative Diseases
Sandhu, J. K., & Kulka, M. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22031093 · Cited by 90
Dietary nutrition for neurological disease therapy: Current status and future directions
Mao, X., Yin, X., Guan, Q.-W., Xia, Q., Yang, N., Zhou, H., Liu, Z., & Jin, W. (2021) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2021.107861 · Cited by 85
In Pursuit of Healthy Aging: Effects of Nutrition on Brain Function
Melzer, T. M., Manosso, L. M., Yau, S., Gil‐Mohapel, J., & Brocardo, P. S. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22095026 · Cited by 97
Natural Polysaccharides as Preventive and Therapeutic Horizon for Neurodegenerative Diseases
Dhahri, M., Alghrably, M., Mohammed, H. A., Badshah, S. L., Noreen, N., Mouffouk, F., Rayyan, S., Qureshi, K. A., Mahmood, D., Lachowicz, J. I., et al. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics14010001 · Cited by 86
Alzheimer’s disease as a viral disease: Revisiting the infectious hypothesis
Bruno, F., Abondio, P., Bruno, R., Ceraudo, L., Paparazzo, E., Citrigno, L., Luiselli, D., Bruni, A. C., Passarino, G., Colao, R., et al. (2023) · Ageing Research Reviews · doi:10.1016/j.arr.2023.102068 · Cited by 88
Simon, E., Obst, J., & Gomez-Nicola, D. (2019) · Neuroscience · doi:10.1016/j.neuroscience.2018.01.059 · Cited by 83
Fischer, A. (2015) · NeuroImage · doi:10.1016/j.neuroimage.2015.11.039 · Cited by 82
Obesity Accelerates Alzheimer-Related Pathology inAPOE4but notAPOE3Mice
Moser, V. A., & Pike, C. J. (2017) · eNeuro · doi:10.1523/eneuro.0077-17.2017 · Cited by 85
Weil, R., Laplantine, E., Curic, S., & Génin, P. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01243 · Cited by 83
Mudò, G., Frinchi, M., Nuzzo, D., Scaduto, P., Plescia, F., Massenti, M. F., Carlo, M. D., Cannizzaro, C., Cassata, G., Cicero, L. L., et al. (2019) · Journal of Neuroinflammation · doi:10.1186/s12974-019-1417-4 · Cited by 87
Kaya, I., Jennische, E., Lange, S., Baykal, A. T., Malmberg, P., & Fletcher, J. S. (2020) · Journal of Neurochemistry · doi:10.1111/jnc.14999 · Cited by 85
Molecular signature of extracellular matrix pathology in schizophrenia
Pantazopoulos, H., Katsel, P., Haroutunian, V. H., Chelini, G., Klengel, T., & Berretta, S. (2020) · European Journal of Neuroscience · doi:10.1111/ejn.15009 · Cited by 83
Tylek, K., Trojan, E., Regulska, M., Lacivita, E., Leopoldo, M., & Basta‐Kaim, A. (2021) · Pharmacological Reports · doi:10.1007/s43440-021-00271-x · Cited by 83
Kuwar, R., Rolfe, A., Di, L., Blevins, H., Xu, Y., Sun, X., Bloom, G. S., Zhang, S., & Sun, D. (2021) · Journal of Alzheimer s Disease · doi:10.3233/jad-210400 · Cited by 82
Effects of Natural Polyphenols on Oxidative Stress-Mediated Blood-Brain Barrier Dysfunction
Kim, Y., Cho, A. Y., Kim, H. C., Ryu, D., Jo, S. A., & Jung, Y. (2022) · Antioxidants · doi:10.3390/antiox11020197 · Cited by 87
Zuo, W., & Wu, J. (2022) · Therapeutic Advances in Chronic Disease · doi:10.1177/20406223211063020 · Cited by 88
Edavettal, S. C., Cejudo–Martín, P., Dasgupta, B., Yang, D., Buschman, M. D., Domingo, D. L., Kolen, K. V., Jaiprasart, P., Gordon, R. E., Schutsky, K., et al. (2022) · Med · doi:10.1016/j.medj.2022.09.007 · Cited by 86
Zhang, Y., Shen, Y., Liufu, N., Liu, L., Li, W., Shi, Z., Zheng, H., Mei, X., Chen, C.-Y., Jiang, Z., et al. (2023) · Molecular Psychiatry · doi:10.1038/s41380-023-02216-7 · Cited by 83
Fu, R., Harn, H., Liu, S., Chen, C., Chang, W.-L., Chen, Y.-M., Huang, J.-E., Li, R.-J., Tsai, S.-Y., Hung, H., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0085305 · Cited by 89
Dong, Y., Chen, Z., Zhao, Z., Yang, D., Yan, H., Ji, J., & Sun, X. (2016) · Journal of Neuroinflammation · doi:10.1186/s12974-016-0527-5 · Cited by 85
Dias, K. S. T., de Paula, C. T., dos Santos, T., Souza, I. N. D. O., Boni, M. S., Guimarães, M. J. R., da Silva, F. M. R., Castro, N. G., Neves, G. A., Veloso, C. C., et al. (2017) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2017.02.043 · Cited by 83
Molecular Magnetic Resonance Imaging of Endothelial Activation in the Central Nervous System
Gauberti, M., Fournier, A. P., Docagne, F., Vivien, D., & de Lizarrondo, S. M. (2018) · Theranostics · doi:10.7150/thno.22662 · Cited by 93
Che, H., Li, Q., Zhang, T., Ding, L., Zhang, L., Shi, H., Yanagita, T., Xue, C., Chang, Y., & Wang, Y. (2018) · Food & Function · doi:10.1039/c8fo00643a · Cited by 84
Scholtzova, H., Do, E., Dhakal, S., Sun, Y., Liu, S., Mehta, P. D., & Wisniewski, T. (2017) · The Journal of Neuroscience · doi:10.1523/jneurosci.1967-16.2016 · Cited by 82
Greve, H. J., Dunbar, A. L., Lombo, C. G., Ahmed, C., Thang, M., Messenger, E. J., Mumaw, C. L., Johnson, J. A., Kodavanti, U. P., Oblak, A. L., et al. (2023) · Brain · doi:10.1093/brain/awac113 · Cited by 82
Analysis of Shared Heritability in Common Disorders of the Brain
(2016) · doi:10.1101/048991 · Cited by 82
Chiquita, S., Rodrigues‐Neves, A. C., Baptista, F. I., Carecho, R., Moreira, P. I., Castelo-Branco, M. S., & Ambrósio, A. F. (2019) · Molecular Neurobiology · doi:10.1007/s12035-018-1461-6 · Cited by 86
Association between alcohol consumption and Alzheimer's disease: A Mendelian randomization study
Andrews, S. J., Goate, A., & Anstey, K. J. (2020) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2019.09.086 · Cited by 82
Zhu, G., Zhao, J., Zhang, H., Chen, W., & Wang, G. (2021) · Nutrients · doi:10.3390/nu13051602 · Cited by 89
Chatterjee, P., Vermunt, L., Gordon, B. A., Pedrini, S., Boonkamp, L., Armstrong, N. J., Xiong, C., Singh, A. K., Li, Y., Sohrabi, H. R., et al. (2022) · Alzheimer s & Dementia · doi:10.1002/alz.12879 · Cited by 91
Gameiro‐Ros, I., Michalska, P., Tenti, G., Cores, Á., Buendía, I., Rojo, A. I., Georgakopoulos, N., Hernández-Guijo, J. M., Ramos, M. T., Wells, G., et al. (2017) · Scientific Reports · doi:10.1038/srep45701 · Cited by 83
Alzheimer's Disease Risk Factor Pyk2 Mediates Amyloid-β-Induced Synaptic Dysfunction and Loss
Salazar, S. V., Cox, T. O., Lee, S., Brody, A. H., Chyung, A. S., Haas, L. T., & Strittmatter, S. M. (2019) · The Journal of Neuroscience · doi:10.1523/jneurosci.1873-18.2018 · Cited by 77
Lista, S., Imbimbo, B. P., Grasso, M., Fidilio, A., Emanuele, E., Minoretti, P., López-Ortiz, S., Martín-Hernández, J., Gabelle, A., Caruso, G., et al. (2024) · Journal of Neuroinflammation · doi:10.1186/s12974-024-03163-y · Cited by 81
Self-citationAPOE ε4 associates with microglial activation independently of Aβ plaques and tau tangles
Ferrari-Souza, J. P., Lussier, F. Z., Leffa, D. T., Therriault, J., Tissot, C., Bellaver, B., Ferreira, P. C. L., Malpetti, M., Wang, Y.-T., Povala, G., et al. (2023) · Science Advances · doi:10.1126/sciadv.ade1474 · Cited by 81
Huang, L., Wang, S., Ma, F., Zhang, Y., Peng, Y., Xing, C., Feng, Y., Wang, X., & Peng, Y. (2018) · Pharmacological Research · doi:10.1016/j.phrs.2018.08.007 · Cited by 80
Tripathi, A., Choubey, P. K., Sharma, P. A., Seth, A., Tripathi, P. N., Tripathi, M. K., Prajapati, S. K., Krishnamurthy, S., & Shrivastava, S. K. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.111707 · Cited by 81
Potential Role of Tocotrienols on Non-Communicable Diseases: A Review of Current Evidence
Wong, S. K., Kamisah, Y., Mohamed, N., Muhammad, N., Masbah, N., Azlina, M. F. N., Mohamed, I. N., Shuid, A. N., Saad, Q. M., Abdullah, A., et al. (2020) · Nutrients · doi:10.3390/nu12010259 · Cited by 80
Aufschnaiter, A., Kohler, V., Khalifa, S. A. M., El‐Wahed, A. A. A., Du, M., El-Seedi, H. R., & Büttner, S. (2020) · Toxins · doi:10.3390/toxins12020066 · Cited by 81
Asken, B. M., Elahi, F. M., Joie, R. L., Strom, A., Staffaroni, A. M., Lindbergh, C. A., Apple, A. C., You, M. Y., Weiner‐Light, S., Brathaban, N., et al. (2020) · Journal of Alzheimer s Disease · doi:10.3233/jad-200755 · Cited by 81
Paladugu, L., Gharaibeh, A., Kolli, N., Learman, C. R., Hall, T. C., Li, L., Rossignol, J., Maiti, P., & Dunbar, G. L. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22020860 · Cited by 79
RetractedLuo, M., Lee, L. K. C., Peng, B., Choi, C. H. J., Tong, W. Y., & Voelcker, N. H. (2022) · Advanced Science · doi:10.1002/advs.202201740 · Cited by 85
Association of Midlife Inflammatory Markers With Cognitive Performance at 10-Year Follow-up
Kipinoinen, T., Toppala, S., Rinne, J. O., Viitanen, M. H., Jula, A., & Ekblad, L. L. (2022) · Neurology · doi:10.1212/wnl.0000000000201116 · Cited by 81
Ge, K., Li, Z., Wang, A., Bai, Z., Zhang, X., Zheng, X., Liu, Z., & Gao, F. (2023) · ACS Nano · doi:10.1021/acsnano.2c08499 · Cited by 83
Loeffler, D. A. (2023) · Journal of Alzheimer s Disease Reports · doi:10.3233/adr-230025 · Cited by 90
Targeting neuroinflammation in Alzheimer’s disease: evidence for NSAIDs and novel therapeutics
Deardorff, W. J., & Grossberg, G. T. (2016) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2016.1200972 · Cited by 85
Doxycycline counteracts neuroinflammation restoring memory in Alzheimer's disease mouse models
Balducci, C., Santamaria, G., Vitola, P. L., Brandi, E., Grandi, F., Viscomi, A. R., Beeg, M., Gobbi, M., Salmona, M., Ottonello, S., et al. (2018) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2018.06.002 · Cited by 83
Flore, G., Preti, A., Carta, M. G., Deledda, A., Fosci, M., Nardi, A. E., Loviselli, A., & Velluzzi, F. (2022) · Nutrients · doi:10.3390/nu14061259 · Cited by 80
Kiyota, T., Machhi, J., Lu, Y., Dyavarshetty, B., Nemati, M., Yokoyama, I., Mosley, R. L., & Gendelman, H. E. (2018) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2018.03.009 · Cited by 80
Shin, M., Liu, Q. F., Choi, B., Shin, C., Lee, B., Yuan, C., Song, Y. J., Yun, H. S., Lee, I.-S., Koo, B.-S., et al. (2020) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.b19-00495 · Cited by 80
Walter, J. (2016) · Journal of Biological Chemistry · doi:10.1074/jbc.r115.704981 · Cited by 80
Souza, L. C., Jessé, C. R., Antunes, M. S., Ruff, J. R., Janner, D. E., Gomes, N. S., Donato, F., Giacomeli, R., & Boeira, S. P. (2016) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2016.03.002 · Cited by 83
Duncombe, J., Lennen, R. J., Jansen, M. A., Marshall, I., Wardlaw, J. M., & Horsburgh, K. J. (2016) · Neuropathology and Applied Neurobiology · doi:10.1111/nan.12375 · Cited by 85
Fan, D., Liu, L., Wu, Z., & Cao, M. (2018) · Current Neuropharmacology · doi:10.2174/1570159x16666180419141613 · Cited by 80
An update on the interactions between Alzheimer's disease, autophagy and inflammation
Bostancıklıoğlu, M. (2019) · Gene · doi:10.1016/j.gene.2019.04.040 · Cited by 78
Salvadores, N., Moreno‐González, I., Gamez, N., Quiroz, G., Vegas‐Gomez, L., Escandón, M., Jiménez, S., Vitórica, J., Gutiérrez, A., Soto, C. A., et al. (2022) · Acta Neuropathologica Communications · doi:10.1186/s40478-022-01332-9 · Cited by 87
Pfundstein, G., Nikonenko, A. G., & Sytnyk, V. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.969547 · Cited by 89
Adoptive therapy with amyloid-β specific regulatory T cells alleviates Alzheimer's disease
Yang, H., Park, S., Baek, H., Lee, C., Chung, G., Liu, X., Lee, J. H., Kim, B., Kwon, M., Choi, H.-J., et al. (2022) · Theranostics · doi:10.7150/thno.75965 · Cited by 83
Chronic effects of inflammation on tauopathies
Langworth-Green, C., Patel, S., Jaunmuktane, Z., Jabbari, E., Morris, H. R., Thom, M., Lees, A. J., Hardy, J., Zandi, M. S., & Duff, K. (2023) · The Lancet Neurology · doi:10.1016/s1474-4422(23)00038-8 · Cited by 85
Cell-type-specific co-expression inference from single cell RNA-sequencing data
Su, C., Xu, Z., Shan, X., Cai, B., Zhao, H., & Zhang, J. (2023) · Nature Communications · doi:10.1038/s41467-023-40503-7 · Cited by 93
Duan, M., Xu, Y., Li, Y., Feng, H., & Chen, Y. (2024) · Journal of Neuroinflammation · doi:10.1186/s12974-024-03101-y · Cited by 85
The roles of microglia and astrocytes in neuroinflammation of Alzheimer’s disease
Han, J., Zhang, Z., Zhang, P., Yu, Q., Cheng, Q., Lu, Z., & Zong, S. (2025) · Frontiers in Neuroscience · doi:10.3389/fnins.2025.1575453 · Cited by 97
Rajaram, S., Valls‐Pedret, C., Cofán, M., Sabaté, J., Serra‐Mir, M., Pérez-Heras, A., Aréchiga, A. E., Casaroli-Marano, R. P., Alforja, S., Sala‐Vila, A., et al. (2017) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2016.00333 · Cited by 79
Metadata
- Authors
- Heneka, M. T., Carson, M. J., Khoury, J. E., Landreth, G. E., Brosseron, F., Feinstein, D. L., Jacobs, A. H., Wyss-Coray, T., Vitorica, J., Ransohoff, R. M., Herrup, K., Frautschy, S. A., Finsen, B., Brown, G. C., Verkhratsky, A., Yamanaka, K., Koistinaho, J., Latz, E., Halle, A., Petzold, G. C., Town, T., Morgan, D., Shinohara, M. L., Perry, V. H., Holmes, C., Bazan, N. G., Brooks, D. J., Hunot, S., Joseph, B., Deigendesch, N., Garaschuk, O., Boddeke, E., Dinarello, C. A., Breitner, J. C., Cole, G. M., Golenbock, D. T., & Kummer, M. P.
- Affiliations
- University of Bonn (DE)
- University of California, Riverside (US)
- Case Western Reserve University (US)
- German Center for Neurodegenerative Diseases (DE)
- University of Illinois Chicago (US)
- University of Münster (DE)
- Cleveland Clinic (US)
- Hong Kong University of Science and Technology (HK)
- University of California, Los Angeles (US)
- University of Southern Denmark (DK)
- University of Cambridge (GB)
- Ikerbasque (ES)
- RIKEN (JP)
- Center of Advanced European Studies and Research (DE)
- University of Southern California (US)
- Duke Medical Center (US)
- Southampton General Hospital (GB)
- Southern Health NHS Foundation Trust (GB)
- Louisiana State University (US)
- Hammersmith Hospital (GB)
- Centre National de la Recherche Scientifique (FR)
- Karolinska Institutet (SE)
- Max Planck Institute for Infection Biology (DE)
- University of Tübingen (DE)
- University Medical Center Groningen (NL)
- University of Colorado Denver (US)
- Douglas Mental Health University Institute (CA)
- University of Massachusetts Chan Medical School (US)
- Corresponding author
- Heneka, Michael T
- ORCID
- Heneka, Michael T
- Carson, Monica J
- Landreth, Gary E
- Brosseron, Frederic
- Feinstein, Douglas L
- Jacobs, Andreas H
- Ransohoff, Richard M
- Herrup, Karl
- Frautschy, Sally A
- Finsen, Bente
- Brown, Guy C
- Verkhratsky, Alexei
- Yamanaka, Koji
- Latz, Eicke
- Halle, Annett
- Petzold, Gabor C
- Shinohara, Mari L
- Perry, V Hugh
- Holmes, Clive
- Bazan, Nicolas G
- Brooks, David J
- Hunot, Stéphane
- Joseph, Bertrand
- Deigendesch, Nikolaus
- Garaschuk, Olga
- Boddeke, Erik
- Dinarello, Charles A
- Breitner, John C
- Golenbock, Douglas T
- Kummer, Markus P
- Venue
- The Lancet Neurology
- Publisher
- Elsevier BV
- Published
- 2015-04
- Volume
- 14
- Issue
- 4
- Pages
- 388-405
- ISSN
- 1474-4422 (ISSN-L)
- PMC
- PMC5909703
- OpenAlex
- W2087243986
- Cited by
- 6,226
- References
- 244
- Citations by year
- 2026: 686 · 2025: 708 · 2024: 713 · 2023: 640 · 2022: 665 · 2021: 620 · 2020: 554 · 2019: 506 · 2018: 406 · 2017: 342 · 2016: 259 · 2015: 110
- FWCI
- 29.69
- Type
- journal article
- Language
- en
- Open access
- green
- europepmc.org
- Locations
- The Lancet Neurology (publishedVersion)
- PubMed (publishedVersion)
- Research Explorer (The University of Manchester) (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- ePrints Soton (University of Southampton) (acceptedVersion)
- Open Repository and Bibliography (University of Luxembourg) (submittedVersion, other-oa)
- eScholarship (California Digital Library) (submittedVersion)
- The Journal of the American Medical Association (JAMA) Network (American Medical Association) (submittedVersion)
- HAL (submittedVersion, other-oa)
- Max Planck Digital Library (submittedVersion)
- Deposito de Investigacion Universidad de Sevilla (University of Seville) (submittedVersion, cc-by-nc-nd)
- DZNE Pub (submittedVersion)
- MPG.PuRe (Max Planck Society) (submittedVersion)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion)
- Rare & Special e-Zone (The Hong Kong University of Science and Technology) (submittedVersion)
- Radboud Repository (Radboud University) (submittedVersion)
- University of Southern Denmark Research Portal (University of Southern Denmark) (submittedVersion)
- Funders
- Medical Research Council (MR/L010593/1)
- Japan Society for the Promotion of Science (26293208)
- National Institute on Aging (R21AG053884)
- National Institute of Neurological Disorders and Stroke (R01NS059005, R01NS076794)
- Topics
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Keywords
- Alzheimer's disease, neuroinflammation, innate immunity, microglia, astrocytes, pattern recognition receptors, protein aggregation, misfolded proteins, inflammatory mediators, systemic inflammation, obesity, genetic risk factors, therapeutic target
- MeSH terms
- Alzheimer Disease, Animals, Anti-Inflammatory Agents, Non-Steroidal, Astrocytes, Brain Injuries, Clinical Trials as Topic, Disease Models, Animal, Humans, Immunity, Innate, Immunization, Inflammation, Locus Coeruleus, Obesity, Phagocytosis, Risk Factors, Severity of Illness Index, Biomarkers, Protein Folding, Microglia, Disease Progression, Nootropic Agents, Inflammation Mediators
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
